In depth understanding examples of how the tumor genetic background can influence TME composition and response to treatments include, for example, evidence that loss of the PTEN tumor suppressor results in immunotherapy resistance, by directly inducing the T-cell inhibitor PD-L1 in several malignancies, including in mouse pancreatic cancer models [247,248,249]. This evidence concerns the gene CD274 and pancreatic neoplasm.